Madrigal Pharmaceuticals Q4 revenue rises sharply on Rezdiffra sales

Madrigal Pharmaceuticals

19/02/2026 12:10

Overview

Biopharmaceutical firm reported Q4 revenue of $321.1 mln, up significantly from last year

Company reported net loss for Q4 despite revenue growth

Company expanded MASH pipeline with new programs and partnerships

Outlook

Madrigal expects robust Rezdiffra sales growth in 2026 due to increased disease awareness

Company plans IND-enabling activities for siRNA programs in 2026

Madrigal to consult with FDA on Phase 2 combination trial design this year

Result Drivers

REZDIFFRA SALES GROWTH - Significant increase in Rezdiffra sales attributed to market penetration and disease awareness

PIPELINE EXPANSION - Expanded MASH pipeline with new programs and partnerships to enhance treatment options

OPERATING EXPENSES - Increase due to commercial activities for Rezdiffra and business development transactions

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Product Revenue
$321.08 mln
Q4 EPS
-$2.57
Q4 Net Income
-$58.58 mln
Q4 Operating Expenses
$380.69 mln
Q4 Operating Income
-$59.61 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Madrigal Pharmaceuticals Inc is $638.00, about 29.8% above its February 18 closing price of $491.49

The stock recently traded at 3,021 times the next 12-month earnings vs. a P/E of 179 three months ago

Press Release: ID:nGNX8X4tRq

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)